ES2763931T3 - Genes Nano46 y métodos para predecir el resultado del cáncer de mama - Google Patents
Genes Nano46 y métodos para predecir el resultado del cáncer de mama Download PDFInfo
- Publication number
- ES2763931T3 ES2763931T3 ES13794236T ES13794236T ES2763931T3 ES 2763931 T3 ES2763931 T3 ES 2763931T3 ES 13794236 T ES13794236 T ES 13794236T ES 13794236 T ES13794236 T ES 13794236T ES 2763931 T3 ES2763931 T3 ES 2763931T3
- Authority
- ES
- Spain
- Prior art keywords
- genes
- intrinsic
- ror
- breast cancer
- score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 163
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 114
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 113
- 238000000034 method Methods 0.000 title claims abstract description 90
- 230000014509 gene expression Effects 0.000 claims abstract description 138
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 93
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 65
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract description 49
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract description 49
- 208000026535 luminal A breast carcinoma Diseases 0.000 claims abstract description 43
- 208000026534 luminal B breast carcinoma Diseases 0.000 claims abstract description 41
- 230000035755 proliferation Effects 0.000 claims abstract description 24
- 101150029707 ERBB2 gene Proteins 0.000 claims abstract description 13
- 101150078635 18 gene Proteins 0.000 claims abstract description 4
- 102100033393 Anillin Human genes 0.000 claims abstract description 4
- 108700020472 CDC20 Proteins 0.000 claims abstract description 4
- 101150023302 Cdc20 gene Proteins 0.000 claims abstract description 4
- 102100027047 Cell division control protein 6 homolog Human genes 0.000 claims abstract description 4
- 102100038099 Cell division cycle protein 20 homolog Human genes 0.000 claims abstract description 4
- 102100023344 Centromere protein F Human genes 0.000 claims abstract description 4
- 102100031219 Centrosomal protein of 55 kDa Human genes 0.000 claims abstract description 4
- 101710092479 Centrosomal protein of 55 kDa Proteins 0.000 claims abstract description 4
- 102100037858 G1/S-specific cyclin-E1 Human genes 0.000 claims abstract description 4
- 101000732632 Homo sapiens Anillin Proteins 0.000 claims abstract description 4
- 101000914465 Homo sapiens Cell division control protein 6 homolog Proteins 0.000 claims abstract description 4
- 101000907941 Homo sapiens Centromere protein F Proteins 0.000 claims abstract description 4
- 101000738568 Homo sapiens G1/S-specific cyclin-E1 Proteins 0.000 claims abstract description 4
- 101001050567 Homo sapiens Kinesin-like protein KIF2C Proteins 0.000 claims abstract description 4
- 101001112162 Homo sapiens Kinetochore protein NDC80 homolog Proteins 0.000 claims abstract description 4
- 101000590482 Homo sapiens Kinetochore protein Nuf2 Proteins 0.000 claims abstract description 4
- 101000721146 Homo sapiens Origin recognition complex subunit 6 Proteins 0.000 claims abstract description 4
- 101000945496 Homo sapiens Proliferation marker protein Ki-67 Proteins 0.000 claims abstract description 4
- 101000575639 Homo sapiens Ribonucleoside-diphosphate reductase subunit M2 Proteins 0.000 claims abstract description 4
- 101001087372 Homo sapiens Securin Proteins 0.000 claims abstract description 4
- 101000809797 Homo sapiens Thymidylate synthase Proteins 0.000 claims abstract description 4
- 101000807354 Homo sapiens Ubiquitin-conjugating enzyme E2 C Proteins 0.000 claims abstract description 4
- 101000837581 Homo sapiens Ubiquitin-conjugating enzyme E2 T Proteins 0.000 claims abstract description 4
- 102100023424 Kinesin-like protein KIF2C Human genes 0.000 claims abstract description 4
- 102100023890 Kinetochore protein NDC80 homolog Human genes 0.000 claims abstract description 4
- 102100032431 Kinetochore protein Nuf2 Human genes 0.000 claims abstract description 4
- 102100024299 Maternal embryonic leucine zipper kinase Human genes 0.000 claims abstract description 4
- 101710154611 Maternal embryonic leucine zipper kinase Proteins 0.000 claims abstract description 4
- 102100025201 Origin recognition complex subunit 6 Human genes 0.000 claims abstract description 4
- 102100034836 Proliferation marker protein Ki-67 Human genes 0.000 claims abstract description 4
- 102100026006 Ribonucleoside-diphosphate reductase subunit M2 Human genes 0.000 claims abstract description 4
- 101100010298 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pol2 gene Proteins 0.000 claims abstract description 4
- 102100033004 Securin Human genes 0.000 claims abstract description 4
- 102100038618 Thymidylate synthase Human genes 0.000 claims abstract description 4
- 102100037256 Ubiquitin-conjugating enzyme E2 C Human genes 0.000 claims abstract description 4
- 102100028705 Ubiquitin-conjugating enzyme E2 T Human genes 0.000 claims abstract description 4
- KIAPWMKFHIKQOZ-UHFFFAOYSA-N 2-[[(4-fluorophenyl)-oxomethyl]amino]benzoic acid methyl ester Chemical compound COC(=O)C1=CC=CC=C1NC(=O)C1=CC=C(F)C=C1 KIAPWMKFHIKQOZ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 102100029075 Exonuclease 1 Human genes 0.000 claims abstract description 3
- 101000918264 Homo sapiens Exonuclease 1 Proteins 0.000 claims abstract description 3
- 241001609030 Brosme brosme Species 0.000 claims abstract 2
- 241000023320 Luma <angiosperm> Species 0.000 claims abstract 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims abstract 2
- 108010038795 estrogen receptors Proteins 0.000 claims description 37
- 238000004458 analytical method Methods 0.000 claims description 29
- 230000004083 survival effect Effects 0.000 claims description 21
- 102000003998 progesterone receptors Human genes 0.000 claims description 13
- 108090000468 progesterone receptors Proteins 0.000 claims description 13
- 230000004044 response Effects 0.000 claims description 11
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 102100038595 Estrogen receptor Human genes 0.000 claims 2
- 239000000523 sample Substances 0.000 description 177
- 238000012360 testing method Methods 0.000 description 71
- 238000009396 hybridization Methods 0.000 description 44
- 210000001519 tissue Anatomy 0.000 description 44
- 238000012423 maintenance Methods 0.000 description 36
- 102000015694 estrogen receptors Human genes 0.000 description 35
- 238000003556 assay Methods 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 25
- 238000004422 calculation algorithm Methods 0.000 description 21
- 239000013074 reference sample Substances 0.000 description 19
- 239000012472 biological sample Substances 0.000 description 18
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 230000004913 activation Effects 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- 238000010606 normalization Methods 0.000 description 14
- 210000000481 breast Anatomy 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 238000004393 prognosis Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000013642 negative control Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 230000022131 cell cycle Effects 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 10
- 239000013614 RNA sample Substances 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 238000002123 RNA extraction Methods 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000009261 endocrine therapy Methods 0.000 description 8
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 8
- 210000001165 lymph node Anatomy 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 239000013615 primer Substances 0.000 description 8
- 229960001603 tamoxifen Drugs 0.000 description 8
- 238000012549 training Methods 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 238000013145 classification model Methods 0.000 description 7
- 238000013480 data collection Methods 0.000 description 7
- 108091008039 hormone receptors Proteins 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 238000002493 microarray Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012552 review Methods 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 102000001301 EGF receptor Human genes 0.000 description 6
- 108060006698 EGF receptor Proteins 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 239000000186 progesterone Substances 0.000 description 5
- 229960003387 progesterone Drugs 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- -1 EXOl Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 108700031843 GRB7 Adaptor Proteins 0.000 description 4
- 101150052409 GRB7 gene Proteins 0.000 description 4
- 102100033107 Growth factor receptor-bound protein 7 Human genes 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 102100029511 26S proteasome regulatory subunit 6B Human genes 0.000 description 3
- 102100028104 39S ribosomal protein L19, mitochondrial Human genes 0.000 description 3
- 101100208111 Arabidopsis thaliana TRX5 gene Proteins 0.000 description 3
- 102100026031 Beta-glucuronidase Human genes 0.000 description 3
- 108010058546 Cyclin D1 Proteins 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 3
- 101001125524 Homo sapiens 26S proteasome regulatory subunit 6B Proteins 0.000 description 3
- 101001079803 Homo sapiens 39S ribosomal protein L19, mitochondrial Proteins 0.000 description 3
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 3
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 3
- 101000616974 Homo sapiens Pumilio homolog 1 Proteins 0.000 description 3
- 101100420560 Homo sapiens SLC39A6 gene Proteins 0.000 description 3
- 101000707546 Homo sapiens Splicing factor 3A subunit 1 Proteins 0.000 description 3
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 3
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102100021672 Pumilio homolog 1 Human genes 0.000 description 3
- 102100031713 Splicing factor 3A subunit 1 Human genes 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 3
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 3
- 102100023144 Zinc transporter ZIP6 Human genes 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 208000030776 invasive breast carcinoma Diseases 0.000 description 3
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000000513 principal component analysis Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 102100040881 60S acidic ribosomal protein P0 Human genes 0.000 description 2
- 101000673456 Homo sapiens 60S acidic ribosomal protein P0 Proteins 0.000 description 2
- 238000008149 MammaPrint Methods 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 239000002313 adhesive film Substances 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000007417 hierarchical cluster analysis Methods 0.000 description 2
- 208000027706 hormone receptor-positive breast cancer Diseases 0.000 description 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000013178 mathematical model Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000003909 pattern recognition Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 101150052384 50 gene Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102100027161 BRCA2-interacting transcriptional repressor EMSY Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 1
- 101001057996 Homo sapiens BRCA2-interacting transcriptional repressor EMSY Proteins 0.000 description 1
- 101000868643 Homo sapiens G2/mitotic-specific cyclin-B1 Proteins 0.000 description 1
- 101000593405 Homo sapiens Myb-related protein B Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- 239000004594 Masterbatch (MB) Substances 0.000 description 1
- 102100034670 Myb-related protein B Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101001122448 Rattus norvegicus Nociceptin receptor Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 102000000763 Survivin Human genes 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000009260 adjuvant endocrine therapy Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013481 data capture Methods 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000029691 metastatic malignant neoplasm in the lymph nodes Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000012567 pattern recognition method Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000013442 quality metrics Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650209P | 2012-05-22 | 2012-05-22 | |
| US201361753673P | 2013-01-17 | 2013-01-17 | |
| PCT/US2013/042157 WO2013177245A2 (en) | 2012-05-22 | 2013-05-22 | Nano46 genes and methods to predict breast cancer outcome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2763931T3 true ES2763931T3 (es) | 2020-06-01 |
Family
ID=49624503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13794236T Active ES2763931T3 (es) | 2012-05-22 | 2013-05-22 | Genes Nano46 y métodos para predecir el resultado del cáncer de mama |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20130337444A1 (enExample) |
| EP (1) | EP2852689B1 (enExample) |
| JP (1) | JP6325530B2 (enExample) |
| CN (2) | CN111500718A (enExample) |
| AU (1) | AU2013266419B2 (enExample) |
| BR (1) | BR112014029300A2 (enExample) |
| CA (1) | CA2874492C (enExample) |
| ES (1) | ES2763931T3 (enExample) |
| IL (1) | IL235795B (enExample) |
| IN (1) | IN2014MN02418A (enExample) |
| MX (1) | MX369628B (enExample) |
| WO (1) | WO2013177245A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2297359T4 (pl) | 2008-05-30 | 2014-07-31 | Univ North Carolina Chapel Hill | Profile ekspresji genów do przewidywania skutków raka piersi |
| AU2012229123B2 (en) | 2011-03-15 | 2017-02-02 | British Columbia Cancer Agency Branch | Methods of treating breast cancer with anthracycline therapy |
| GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
| EP2785873A4 (en) | 2011-11-30 | 2015-11-11 | Univ North Carolina | METHOD FOR THE TREATMENT OF BREAST CANCER WITH TAXAN THERAPY |
| DK3511423T4 (da) | 2012-10-17 | 2024-07-29 | Spatial Transcriptomics Ab | Fremgangsmåder og produkt til optimering af lokaliseret eller rumlig detektion af genekspression i en vævsprøve |
| US20160115551A1 (en) * | 2013-05-13 | 2016-04-28 | Nanostring Technologies, Inc. | Methods to predict risk of recurrence in node-positive early breast cancer |
| EP4234716A3 (en) | 2013-06-25 | 2023-12-06 | Prognosys Biosciences, Inc. | Methods for determining spatial patterns of biological targets in a sample |
| AU2014317843A1 (en) * | 2013-09-09 | 2016-03-24 | British Columbia Cancer Agency Branch | Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy |
| CN113403373B (zh) | 2014-11-21 | 2025-04-11 | 布鲁克空间生物学公司 | 无酶且无扩增的测序 |
| SG11201704177SA (en) | 2014-11-24 | 2017-06-29 | Nanostring Technologies Inc | Methods and apparatuses for gene purification and imaging |
| JP2018500895A (ja) * | 2014-12-09 | 2018-01-18 | キングス・カレッジ・ロンドン | タキサン療法による乳癌治療 |
| EP4119677B1 (en) | 2015-04-10 | 2023-06-28 | Spatial Transcriptomics AB | Spatially distinguished, multiplex nucleic acid analysis of biological specimens |
| US20180209981A1 (en) * | 2015-07-23 | 2018-07-26 | National University Of Singapore | Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment |
| CN109715825B (zh) | 2016-05-16 | 2023-01-06 | 纳米线科技公司 | 用于检测样品中目标核酸的方法 |
| WO2017222453A1 (en) | 2016-06-21 | 2017-12-28 | Hauling Thomas | Nucleic acid sequencing |
| WO2018074865A2 (ko) * | 2016-10-21 | 2018-04-26 | 서울대학교병원 | 유방암 예후 예측용 조성물 및 방법 |
| JP6730525B2 (ja) | 2016-11-21 | 2020-07-29 | ナノストリング テクノロジーズ，インコーポレイティド | 化学組成物とそれを利用する方法 |
| KR101950717B1 (ko) * | 2016-11-23 | 2019-02-21 | 주식회사 젠큐릭스 | 유방암 환자의 화학치료 유용성 예측 방법 |
| WO2018144782A1 (en) * | 2017-02-01 | 2018-08-09 | The Translational Genomics Research Institute | Methods of detecting somatic and germline variants in impure tumors |
| CN120210336A (zh) | 2017-10-06 | 2025-06-27 | 10X基因组学有限公司 | Rna模板化连接 |
| KR102071491B1 (ko) * | 2017-11-10 | 2020-01-30 | 주식회사 디시젠 | 차세대 염기서열분석을 이용한 기계학습 기반 유방암 예후 예측 방법 및 예측 시스템 |
| EP3794146B1 (en) | 2018-05-14 | 2025-12-10 | Bruker Spatial Biology, Inc. | Method for identifying a predetermined nucleotide sequence |
| WO2020094399A1 (en) * | 2018-11-05 | 2020-05-14 | Biontech Diagnostics Gmbh | Predictive methods in breast cancer |
| CN113906147B (zh) | 2019-05-31 | 2024-09-13 | 10X基因组学有限公司 | 检测目标核酸分子的方法 |
| JP7352937B2 (ja) * | 2019-07-19 | 2023-09-29 | 公立大学法人福島県立医科大学 | 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット |
| GB201919032D0 (en) | 2019-12-20 | 2020-02-05 | Cartana Ab | Method of detecting an analyte |
| JP2023514749A (ja) | 2020-02-21 | 2023-04-07 | １０エックス ジェノミクス インコーポレイテッド | 統合型インサイチュ空間的アッセイのための方法および組成物 |
| US12209273B2 (en) | 2020-06-12 | 2025-01-28 | 10X Genomics, Inc. | Nucleic acid assays using click chemistry bioconjugation |
| EP3945136A1 (en) * | 2020-07-28 | 2022-02-02 | Hospital Clínic de Barcelona | In vitro method for the prognosis of patients suffering from her2-positive breast cancer |
| US12297499B2 (en) | 2020-08-17 | 2025-05-13 | 10X Genomics, Inc. | Multicomponent nucleic acid probes for sample analysis |
| US12060603B2 (en) | 2021-01-19 | 2024-08-13 | 10X Genomics, Inc. | Methods for internally controlled in situ assays using padlock probes |
| CA3248919A1 (en) * | 2021-12-20 | 2023-06-29 | Fundacio De Recerca Clinic Barcelona Inst D’Investigacions Biomediques August Pi I Sunyer | DEVELOPMENT AND VALIDATION OF AN IN VITRO PROGNOSIS FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER |
| CN117965734B (zh) * | 2024-02-02 | 2024-09-24 | 奥明星程(杭州)生物科技有限公司 | 一种用于检测硬纤维瘤的基因标志物、试剂盒、检测方法及应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| CA2118806A1 (en) | 1991-09-18 | 1993-04-01 | William J. Dower | Method of synthesizing diverse collections of oligomers |
| AU675054B2 (en) | 1991-11-22 | 1997-01-23 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| DE69829402T2 (de) | 1997-10-31 | 2006-04-13 | Affymetrix, Inc. (a Delaware Corp.), Santa Clara | Expressionsprofile in adulten und fötalen organen |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| US6750015B2 (en) * | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| US20020168639A1 (en) * | 2000-09-22 | 2002-11-14 | Muraca Patrick J. | Profile array substrates |
| WO2005039382A2 (en) * | 2003-06-24 | 2005-05-06 | Genomic Health | Prediction of likelihood of cancer recurrence |
| CA2540167A1 (en) * | 2003-09-29 | 2005-05-12 | Pathwork Informatics, Inc. | Systems and methods for detecting biological features |
| WO2006010150A2 (en) | 2004-07-15 | 2006-01-26 | University Of Utah Research Foundation | Housekeeping genes and methods for identifying the same |
| CN101061480A (zh) * | 2004-09-22 | 2007-10-24 | 三路影像公司 | 用来分析和优化用于癌症诊断的标记候选物的方法和计算机程序产品 |
| EP1954708A4 (en) | 2005-11-23 | 2009-05-13 | Univ Utah Res Found | Methods and compositions involving intrinsic genes |
| EP1963531B1 (en) * | 2005-12-23 | 2011-09-21 | Nanostring Technologies, Inc. | Nanoreporters and methods of manufacturing and use thereof |
| JP5700911B2 (ja) | 2005-12-23 | 2015-04-15 | ナノストリング テクノロジーズ，インコーポレーテッド | 配向され、固定化された巨大分子を含む組成物とその製造法 |
| CA2687292C (en) | 2007-04-10 | 2017-07-04 | Nanostring Technologies, Inc. | Methods and computer systems for identifying target-specific sequences for use in nanoreporters |
| WO2008150512A2 (en) * | 2007-06-04 | 2008-12-11 | University Of Louisville Research Foundation, Inc. | Methods for identifying an increased likelihood of recurrence of breast cancer |
| EP2195467B1 (en) * | 2007-09-06 | 2016-12-14 | bioTheranostics, Inc. | Tumor grading and cancer prognosis in breast cancer |
| PL2297359T4 (pl) * | 2008-05-30 | 2014-07-31 | Univ North Carolina Chapel Hill | Profile ekspresji genów do przewidywania skutków raka piersi |
| ES2614810T3 (es) | 2008-08-14 | 2017-06-02 | Nanostring Technologies, Inc | Nanoindicadores estables |
| MX2012011167A (es) * | 2010-03-31 | 2013-02-07 | Sividon Diagnostics Gmbh | Metodo para prediccion de recurrencia de cancer de mama bajo tratamiento endocrino. |
-
2013
- 2013-05-22 IN IN2418MUN2014 patent/IN2014MN02418A/en unknown
- 2013-05-22 CN CN201911216650.9A patent/CN111500718A/zh active Pending
- 2013-05-22 MX MX2014014275A patent/MX369628B/es active IP Right Grant
- 2013-05-22 ES ES13794236T patent/ES2763931T3/es active Active
- 2013-05-22 US US13/899,656 patent/US20130337444A1/en not_active Abandoned
- 2013-05-22 BR BR112014029300A patent/BR112014029300A2/pt not_active Application Discontinuation
- 2013-05-22 EP EP13794236.3A patent/EP2852689B1/en active Active
- 2013-05-22 CN CN201380038875.4A patent/CN104704128A/zh active Pending
- 2013-05-22 AU AU2013266419A patent/AU2013266419B2/en active Active
- 2013-05-22 WO PCT/US2013/042157 patent/WO2013177245A2/en not_active Ceased
- 2013-05-22 CA CA2874492A patent/CA2874492C/en active Active
- 2013-05-22 JP JP2015514143A patent/JP6325530B2/ja active Active
-
2014
- 2014-11-20 IL IL235795A patent/IL235795B/en active IP Right Grant
-
2020
- 2020-02-14 US US16/792,051 patent/US20200332368A1/en not_active Abandoned
-
2022
- 2022-09-29 US US17/936,745 patent/US20230272476A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL235795B (en) | 2020-02-27 |
| US20230272476A1 (en) | 2023-08-31 |
| JP2015518724A (ja) | 2015-07-06 |
| EP2852689A4 (en) | 2016-05-11 |
| MX2014014275A (es) | 2015-07-06 |
| EP2852689B1 (en) | 2019-12-11 |
| BR112014029300A2 (pt) | 2017-07-25 |
| EP2852689A2 (en) | 2015-04-01 |
| US20200332368A1 (en) | 2020-10-22 |
| MX369628B (es) | 2019-11-14 |
| US20130337444A1 (en) | 2013-12-19 |
| JP6325530B2 (ja) | 2018-05-16 |
| CA2874492A1 (en) | 2013-11-28 |
| AU2013266419A1 (en) | 2014-12-11 |
| IL235795A0 (en) | 2015-01-29 |
| WO2013177245A2 (en) | 2013-11-28 |
| CN104704128A (zh) | 2015-06-10 |
| CN111500718A (zh) | 2020-08-07 |
| IN2014MN02418A (enExample) | 2015-08-14 |
| CA2874492C (en) | 2021-10-19 |
| WO2013177245A3 (en) | 2015-01-29 |
| AU2013266419B2 (en) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2763931T3 (es) | Genes Nano46 y métodos para predecir el resultado del cáncer de mama | |
| JP5971769B2 (ja) | アントラサイクリン療法を用いて乳癌を処置する方法 | |
| ES2650610T3 (es) | Perfiles de expresión génica para predecir desenlaces en cáncer de mama | |
| JP6144695B2 (ja) | タキサン療法を用いて乳癌を処置する方法 | |
| JP2015530072A (ja) | ゲムシタビン療法による乳癌の治療方法 | |
| US20140154681A1 (en) | Methods to Predict Breast Cancer Outcome | |
| US20160115551A1 (en) | Methods to predict risk of recurrence in node-positive early breast cancer | |
| US20150072021A1 (en) | Methods and Kits for Predicting Outcome and Methods and Kits for Treating Breast Cancer with Radiation Therapy | |
| Baker et al. | The molecular detection of micrometastatic breast cancer | |
| EP2278026A1 (en) | A method for predicting clinical outcome of patients with breast carcinoma | |
| Fu et al. | Transcriptomic signatures in breast cancer | |
| JP2018500895A (ja) | タキサン療法による乳癌治療 | |
| Muftah et al. | Molecular-based diagnostic, prognostic and predictive tests in breast cancer | |
| Quintana | Molecular Diagnostics in Breast Cytology |